
From empiric testing to rational design: two decades of progress in phase I trials
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
Shared interests, mutual gain, flexibility and trust are key to building win–win partnerships in drug development.
Presented at the ESMO Virtual Plenaries this year, four key studies in oncology will animate the debate
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years
Long-term outcomes of the phase III study confirm that only the addition of carboplatin to paclitaxel impacts on pathological complete response and event-free survival
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.